May 08, 2019 4:15pm EDT SCYNEXIS Reports First Quarter 2019 Financial Results and Provides Company Update
May 06, 2019 8:30am EDT SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC)
May 01, 2019 8:30am EDT SCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)
Apr 15, 2019 8:30am EDT SCYNEXIS to Discuss ECCMID 2019 Clinical Data, Including Successful Case Studies in Candida auris and Other Difficult-to-Treat Infections, on Conference Call
Apr 08, 2019 8:15am EDT SCYNEXIS Commends the New York Times for its Reporting on Candida auris and Other Drug-Resistant Pathogens
Apr 03, 2019 8:30am EDT SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study, in Data to be Presented at the 29th ECCMID
Mar 14, 2019 4:39pm EDT SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update
Mar 07, 2019 9:34am EST SCYNEXIS is Retiring Existing Term Loan Through a Lower-Interest and Longer-Term Convertible Note
Feb 28, 2019 8:30am EST SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019
